Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger
Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger
Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger
Submitted by
admin
on June 26, 2017 - 9:54am
Source:
Endpoints
News Tags:
Roche
hemophilia A
ACE910
emicizumab
clinical trials
Headline:
Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger
Do Not Allow Advertisers to Use My Personal information
